Chest Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Petty, T.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Petty, T.

Chest, Vol 97, 75-83, Copyright © 1990 by American College of Chest Physicians

ARTICLES

The National Mucolytic Study. Results of a randomized, double-blind, placebo-controlled study of iodinated glycerol in chronic obstructive bronchitis

TL Petty
University of Colorado Health Sciences Center, Denver.

Seventy-four pulmonologists and one allergist were recruited to assess the efficacy and safety of iodinated glycerol (Organidin), 60 mg qid, vs placebo in patients with stable chronic obstructive bronchitis in a randomized, double-blind, placebo-controlled, parallel design. A total of 361 patients (180 to iodinated glycerol and 181 to placebo) who complained of cough and difficulty bringing up sputum entered the eight- week study. Evaluations were based upon eight primary symptom efficacy parameters (cough frequency, cough severity, chest discomfort, dyspnea, ease in bringing up sputum, patient and physician global assessments, and a derived patients' global assessment), and six secondary parameters (frequency of aerosol bronchodilator use, incidence and duration of acute exacerbations, frequency of concomitant medication use, incidences of adverse experiences and dropouts). Cough frequency, cough severity, chest discomfort, patients' ease in bringing up sputum, patients' overall condition, and a derived subject global assessment were significantly (p less than 0.05) improved by iodinated glycerol as compared with placebo within eight weeks of treatment. Dyspnea showed a trend toward improvement and the physicians' global evaluation showed no significant difference between groups. Similar findings were noted in a subgroup analysis of moderately-to-severely affected patients. The mean duration (days) of acute exacerbations and number of dropouts attributable to adverse experiences were significantly less (p less than 0.05) in the iodinated glycerol group.(ABSTRACT TRUNCATED AT 250 WORDS)


This article has been cited by other articles:


Home page
 ChestHome page
B. R. Celli
Update on the Management of COPD
Chest, June 1, 2008; 133(6): 1451 - 1462.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
B. R. Celli
Chronic Obstructive Pulmonary Disease: From Unjustified Nihilism to Evidence-based Optimism.
Proceedings of the ATS, January 1, 2006; 3(1): 58 - 65.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
D. A. Mahler, P. Wire, D. Horstman, C.-N. Chang, J. Yates, T. Fischer, and T. Shah
Effectiveness of Fluticasone Propionate and Salmeterol Combination Delivered via the Diskus Device in the Treatment of Chronic Obstructive Pulmonary Disease
Am. J. Respir. Crit. Care Med., October 15, 2002; 166(8): 1084 - 1091.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
L. J. Dowson, P. J. Guest, and R. A. Stockley
The Relationship of Chronic Sputum Expectoration to Physiologic, Radiologic, and Health Status Characteristics in {alpha}1-Antitrypsin Deficiency (PiZ)
Chest, October 1, 2002; 122(4): 1247 - 1255.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
R. Aalbers, J. Ayres, V. Backer, M. Decramer, P.A. Lier, P. Magyar, J. Malolepszy, R. Ruffin, and G.W. Sybrecht
Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial
Eur. Respir. J., May 1, 2002; 19(5): 936 - 943.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
D. J. Kellerman
P2Y2 Receptor Agonists* : A New Class of Medication Targeted at Improved Mucociliary Clearance
Chest, May 1, 2002; 121(5_suppl): 201S - 205S.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
P. J Poole and P. N Black

BMJ, May 26, 2001; 322(7297): 1271 - 1271.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
T. N. E. T. T. R. Group
Rationale and Design of the National Emphysema Treatment Trial : A Prospective Randomized Trial of Lung Volume Reduction Surgery
Chest, December 1, 1999; 116(6): 1750 - 1761.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
RATIONALE AND DESIGN OF THE NATIONAL EMPHYSEMA TREATMENT TRIAL (NETT): A PROSPECTIVE RANDOMIZED TRIAL OF LUNG VOLUME REDUCTION SURGERY
J. Thorac. Cardiovasc. Surg., September 1, 1999; 118(3): 518 - 528.
[Full Text] [PDF]

Home page
 NEJMHome page
S. E. Weinberger
Recent Advances in Pulmonary Medicine- First of Two Parts
N. Engl. J. Med., May 13, 1993; 328(19): 1389 - 1397.
[Full Text]

Home page
 NEJMHome page
G. T. Ferguson and R. M. Cherniack
Management of Chronic Obstructive Pulmonary Disease
N. Engl. J. Med., April 8, 1993; 328(14): 1017 - 1022.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1990 by the American College of Chest Physicians.